drugset / Trial / NCT01852942
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
Phase 2
Completed
52 enrolled
University of Minnesota
Merck Sharp & Dohme LLC · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study was designed to test the hypothesis that treatment of HIV infected subjects with losartan, an agent with specific anti-inflammatory and anti-fibrotic actions, will: 1. reverse existing lymphoid tissue fibrosis, 2. restore lymphoid tissue architecture, 3. increase the number and improve the function of peripheral and lymphatic CD4 T cells, 4. decrease levels of systemic immune activation (IA), 5. decrease size of the HIV reservoir, and 6. be safe and well tolerated.
Timeline
- Start
- 2014-09
- Primary completion
- 2019-07-16
- Completion
- 2019-07-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Losartan | Other / unclassified | 100 mg | Oral |